Last reviewed 2026-04-20 · How we verify

Bimzelx (BIMEKIZUMAB)

Bimzelx works by binding to interleukin-17A, a protein that promotes inflammation, to reduce symptoms of psoriasis.

At a glance

Mechanism of action

Think of Bimzelx like a key that locks onto a specific protein called interleukin-17A. This protein is like a messenger that tells the body to produce more inflammation, which can cause the symptoms of psoriasis. By binding to this protein, Bimzelx helps to reduce the inflammation and alleviate the symptoms of psoriasis.

Approved indications

• Erythrodermic psoriasis
• Plaque psoriasis
• Pustular psoriasis

Common side effects

• Infections
• Upper respiratory tract infections
• Candida infections (oral candidiasis, oropharyngeal candidiasis, oral fungal infection, fungal pharyngitis, oropharyngitis fungal)
• Suicidal ideation
• Neutropenia
• Eczema
• Otitis externa
• Otitis media
• Pyrexia

Serious adverse events

• Serious infections
• Completed suicide
• Suicide attempts

Key clinical trials

• Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP (PHASE4)
• A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults (PHASE1)
• A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa (PHASE3)
• A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis (PHASE3)
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis (PHASE3)
• A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (PHASE3)
• A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
• A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Bimzelx CI brief — competitive landscape report
• Bimzelx updates RSS · CI watch RSS
• Ucb Japan Co., Ltd. portfolio CI